Home / Health / CT Leads Charge in Gene Therapy for Aging & Cancer
CT Leads Charge in Gene Therapy for Aging & Cancer
21 Mar
Summary
- Gene therapy harnesses the immune system to clear aging cells.
- CAR T-cell therapy shows promise for aging, cancer, and autoimmune diseases.
- Access and affordability are key challenges for advanced gene therapies.
Cutting-edge gene therapies are emerging from research labs and clinical trials in Connecticut, with the potential to combat aging and diseases like cancer. These therapies, including CAR T-cell treatment, are designed to harness the body's own immune system to clear out aging cells or target cancerous ones.
Researchers are optimistic about CAR T-cell therapy's broad applications, extending beyond cancer to autoimmune diseases and even the aging process itself. Scientists are leveraging AI to accelerate innovation in this field.
A legislative push is underway in Connecticut to address access and affordability concerns for these advanced treatments. A proposed bill aims to establish an advisory council to guide public health officials on expanding access to CAR T-cell therapy.
Gene therapies are evolving rapidly, moving from experimental stages to becoming life-saving treatments for rare and severe conditions. Innovations like CRISPR further expand the possibilities for rewriting genetic code to treat diseases.
The high cost of CAR T-cell therapy, potentially exceeding $500,000 per patient, remains a significant barrier. While insurance covers some costs, full coverage is rare, creating a disparity in access for those who can afford the treatment and those who cannot.
